Probiotics as potential biotherapeutics in the management of type 2 diabetes - prospects and perspectives

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 2, 2013, Pages 103-112

  Panwar, Harsh ^a   Rashmi, Hogarehalli Mallappa ^a   Batish, Virender Kumar ^a   Grover, Sunita ^a  

^a NATIONAL DAIRY RESEARCH INSTITUTE   (India)

Author keywords

Gut microbiota; Multifactorial approach; Probiotics; Type 2 diabetes

Indexed keywords

INSULIN; PROBIOTIC AGENT;

BIFIDOBACTERIUM; BIOLOGICAL THERAPY; CELL LINE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DEVELOPING COUNTRY; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ECONOMIC DEVELOPMENT; ENERGY; EPIDEMIC; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; INDIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LIFESTYLE; LIPID PEROXIDATION; MEDICAL RESEARCH; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIAL STATUS; URBANIZATION;

ANIMALS; BIFIDOBACTERIUM; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; HUMANS; LACTOBACILLUS; METAGENOME; PROBIOTICS;

EID: 84873432002     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2376     Document Type: Review

References (57)

1. IDF Diabetes Atlas, Fifth Edition. http://www.idf.org/diabetesatlas.
2. Mengual L, Roura P, Serra M, Montasell M, Prieto G, Bonet S. Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. Cardiovasc Diabetol 2010; 9(1): 14.
3. Cani PD. Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect 2012; 18: 50-53.
4. FAO/WHO. Working group report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada. 2002.
5. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7(4): e34938.
6. Guariguata L. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
7. IDF Diabetes Atlas, Fifth Edition. http://www.worlddiabetesfoundation.org/composite-35.
8. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract 2010; 87: 2-3.
9. Saxena R, Elbers CC, Guo Y, et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012; 90(3): 410-425.
10. Volkmar M, Dedeurwaerder S, Cunha DA, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J 2012; 31(6): 1405-1426.
11. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nat 2010; 464(7285): 59-65.
12. Gerritsen J, Smidt H, Rijkers G, de Vos W. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011; 6(3): 209-240.
13. Fischer A, Whiteson K, Lazarevic V, Hibbs J, Francois P, Schrenzel J. Infant gut microbial colonization and health: recent findings from metagenomics studies. J Integr OMICS 2012; 2(1): 1-16.
14. Martin F-PJ, Collino S, Rezzi S. 1H NMR-based metabonomic applications to decipher gut microbial metabolic influence on mammalian health. Magn Reson Chem 2011; 49: S47-S54.
15. Zhao L, Shen J. Whole body systems approaches for gut microbiota-targeted, preventive healthcare. J Biotechnol 2010; 149: 183-190.
16. Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5(2): e9085.
17. Mallappa RH, Rokana N, Duary RK, Panwar H, Batish VK, Grover S. Management of metabolic syndrome through probiotic and prebiotic interventions. Indian J Endocrinol Metab 2012; 16: 20-27.
18. Nadal I, Santacruz A, Marcos A, et al. Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes 2008; 33(7): 758-767.
19. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008; 32(11): 1720-1724.
20. Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 2008; 88(4): 894-899.
21. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56(7): 1761-1772.
22. Amyot J, Semache M, Ferdaoussi M, Fontés G, Poitout V. Lipopolysaccharides impair insulin gene expression in isolated islets of langerhans via toll-like receptor-4 and NF-κB signalling. PLoS One 2012; 7(4): e36200.
23. Lam YY, Ha CWY, Campbell CR, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012; 7(3): e34233.
24. Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90(5): 1236-1243.
25. Ravussin Y, Koren O, Spor A, et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity 2012; 20(4): 738-747.
26. Forsythe P, Kunze W. Voices from within: gut microbes and the CNS. Cell Mol Life Sci 2012. DOI: 10.1007/s00018-012-1028-z.
27. Freeland KR, Wolever TM. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2010; 103: 460-466.
28. Freeland KR, Wilson C, Wolever TMS. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1year in hyperinsulinaemic human subjects. Br J Nutr 2010; 103(01): 82-90.
29. Yin P, Mohemaiti P, Chen J, et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J Chromatogr B: Analyt Technol Biomed Life Sci 2008; 871(2): 322-327.
30. Zhao X, Zhang Y, Meng X, et al. Effect of a traditional chinese medicine preparation xindi soft capsule on rat model of acute blood stasis: a urinary metabonomics study based on liquid chromatography-mass spectrometry. J Chromatogr B: Analyt Technol Biomed Life Sci 2008; 873(2): 151-158.
31. Zhao X, Fritsche J, Wang J, et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 2010; 6: 362-374.
32. Suhre K, Meisinger C, Doring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 2010; 5(11): e13953.
33. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha induced interleukin 8 expression. Infect Immun 2004; 72: 5308-5314.
34. Clark JA, Coopersmith CM. Intestinal crosstalk - a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007; 28: 384-393.
35. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of Ikappa B-alpha ubiquitination. Science 2000; 289: 1560-1563.
36. Duan F, Curtis KL, March JC. Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 2008; 74(23): 7437-7438.
37. Paszti-Gere E, Szeker K, Csibrik-Nemeth E, et al. Metabolites of Lactobacillus plantarum 2142 prevent oxidative stress-induced overexpression of proinflammatory cytokines in IPEC-J2 Cell Line. Inflammation 2012; 35(4): 1487-1499.
38. Matsuzaki T, Yamazaki R, Hashimoto S, Yokokura T. Antidiabetic effect of an oral administration of Lactobacillus casei in a non-insulin dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Endocr J 1997; 44: 357-365.
39. Matsuzaki T, Nagata Y, Kado S, et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997; 105(7-12): 643-649.
40. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal Microflora: Probiotics and Autoimmunity. J Nutr 2007; 137(3): 798S-802S.
41. Tabuchi M, Ozaki M, Tamura A, et al. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 2003; 67: 1421-1424.
42. Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005; 48: 1565-1575.
43. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007; 23: 62-68.
44. Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res 2008; 75: 1-7.
45. Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf 2008; 1(1): 35-41.
46. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821-830.
47. Andersson U, Bränning C, Ahrné S, et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef Microbes 2010; 1(2): 189-196.
48. Lu Y-C, Yin L-T, Chang W-T, Huang J-S. Effect of Lactobacillus reuteri GMNL-263 treatment on renal fibrosis in diabetic rats. J Biosci Bioeng 2010; 110(6): 709-715.
49. Manirarora JN, Parnell SA, Hu YH, Kosiewich MM, Alard P. NOD dendritic cells stimulated with lactobacilli preferentially produce IL-10 versus IL-12 and decrease diabetes incidence. Clin Dev Immunol 2011; 2011: 1-12.
50. Chen JJ, Wang R, Li X, Wang R. Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp Biol Med 2011; 236(7): 823-831.
51. Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3(9): 559-572.
52. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011; 94(7): 3288-3294.
53. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutr 2012; 28(5): 539-543.
54. Moroti C, Souza Magri L, de Rezende Costa M, Cavallini DCU, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 2012; 11(1): 29.
55. Shao F, Yang C, Liu X, Yang D. Application of microbiological and immunological enteral nutrition in patients with gastrointestinal cancer complicated with diabetes mellitus. Chinese journal of gastrointestinal surgery 2012; 15(5): 476-479.
56. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counseling during pregnancy on colostrum adiponectin concentration: a prospective, randomized, placebo-controlled study. Early Hum Dev 2012; 88(6): 339-344.
57. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 2010; 104(12): 1831-1838.